Abstract Library

#4630 Radiolabelled somatostatin receptor (SSTR) antagonist vs. agonist for peptide receptor radionuclide therapy (PPRT) in patients with SSTR positive neuroendocrine tumours – A retrospective basket study

Introduction: PRRT with lutetium-177 labelled somatostatin receptor (SSTR) agonists ([177Lu]Lu-DOTATATE or [177Lu]Lu-DOTATOC (177Lu-TOC) has limited response rate and durability. The SSTR antagonist [177Lu]Lu-DOTA-JR11 (177Lu-JR11) offers potentially increased tumour doses with better efficacy.

Conference:

Presenting Author: Eigler C

Authors: Eigler C, Mushaweh A, McDougall L, Bauman A, Christ E,

Keywords: Somatostatin Receptor, Neuroendocrine Tumour, DOTA-JR11, DOTA-TOC, Peptide Receptor Radionuclide Therapy,

#4582 Potential significance of individual dosimetry of radionuclide therapy (RLT) using [177Lu]Lu-DOTA-TATE or mixture of [177Lu/90Y]-DOTA-TATE in NET therapy

Introduction: RTL targeted somatostatin receptors is increasingly available. Individual dosimetry performed during RLT of NET may enable to achieve better results of therapy with maintaining its safety.

Conference:

Presenting Author: Opalińska M

Authors: Opalinska M, Kaminski G, Dedecjus M, Kowalska A, Kolodziej M,

Keywords: RLT, DUONEN, GEP-NET, Tandem RLT, dosimetry,

#4356 Assessment of medium- and long-term side effects of Lu-177 treatment in patients with neuroendocrine tumours

Introduction: PRRT with Lu-177 has advanced the treatment of neuroendocrine tumours (NETs), adding a valuable tool against them. This study aims to assess its long-term impact, especially on the most radio-exposed organs—kidneys and bone marrow—and the reproducibility of in vivo clinical trial results (PFS).

Conference:

Presenting Author: Salcedo Cortes S

Authors: Salcedo Cortes S, Ardila Manjarés E, Mari Hualde A, Guzman Cruz A, Casallas Cepeda M,

Keywords: Neuroendocrine tumour (NET), [177Lu]Lu-DOTATATE, Long-term side effects, Radiosensitive organs, PFS,

#4335 Late nephrotoxicity of peptide receptor radionuclide therapy (PRRT) and impact of selected factors – A single centre cohort study

Introduction: The most common side effect of radioligand therapy is renal damage, early or late. However, limited data exist for the long-term side effects and impact of additional risk factors on renal function in patients treated with PRRT.

Conference:

Presenting Author: Sygula A

Authors: Sygula A, Kropinska A, Kotecka-Blicharz A, Gawlik T, Wycislik M,

Keywords: Neuroendocrine tumour, PRRT, nephrotoxicity, yttrium-90, lutetium-177,

#4204 Personalised dosimetry as a key for optimising radioligand therapy (RLT) with [177Lu]Lu-DOTA-TATE or [177Lu]Lu-DOTA-TATE and [90Y]Y-DOTA-TATE in patients with neuroendocrine tumors – The DUONEN multicenter study

Introduction: To date, there is no clear consensus on the optimal RLT regimen. In theory, simultaneous use of two radionuclides with different energy and radiation ranges should be more effective than monotherapy. Individually tailored dosimetry may improve the results of RLT while maintaining its safety.

Conference:

Presenting Author: Opalinska M

Authors: Opalinska M, Kaminski G, Dedecjus M, Kowalska A, Kolodziej M,

Keywords: PRRT, RLT, personalized RTL, NET, Dosimetry,